<DOC>
	<DOCNO>NCT02017561</DOCNO>
	<brief_summary>Metabolic syndrome ( MS ) cluster risk factor cardiovascular disease increase prevalence worldwide insulin resistance central pathophysiology multi-organ deleterious effect . One affected organ , heart , undergoes remodel process increase fibrous tissue impairs global cardiac function . Considering myocardial fibrosis increase myocardial stiffness , one important determinant diastolic function , probably contribute decisively subclinical leave ventricular diastolic dysfunction ( DD ) heart failure preserve ejection fraction patient MS . Since insulin resistance dominant player pathophysiology MS , improvement metabolic profile patient metformin might associate favorable remodel myocardial structure improvement myocardial function . Metformin widely use drug treat type 2 diabetes mellitus consider option treatment high-risk non-diabetic patient MS , addition lifestyle counsel include healthy diet physical activity . In way , aim : ) ass treat non-diabetic patient MS DD metformin addition lifestyle counsel decrease cardiac fibrosis improve diastolic function assess impact functional capacity health-related quality life ( HRQoL ) ; ii ) evaluate biomarkers cardiac remodel inflammation predictive factor response metformin treatment patient . This prospective , randomize , open-label , blinded-endpoint ( PROBE ) trial ( schedule follow-up 24 month ) 2 arm : lifestyle counsel lifestyle counseling plus metformin ( maximum dose 1000mg twice daily ) . The primary endpoint change change mean septal lateral early diastolic mitral annular velocity ( E ' ) ( end 24 month follow-up ) . The secondary endpoint include composite major cardiovascular event ; diastolic function parameter rest ; plasma level insulin , glucose , insulin resistance index , NTproBNP , high-sensitivity C-reactive protein , tumor necrosis factor-α ( TNFα ) , tissue inhibitor matrix metalloproteinase type 1 ( TIMP1 ) growth differentiation factor-15 ( GDF-15 ) ; functional capacity ; epicardial , pericardial abdominal adipose tissue volume , coronary calcium score ; HRQoL .</brief_summary>
	<brief_title>Metformin Diastolic Dysfunction Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Nondiabetic adult age 40 64 year fulfilling American Heart Association/National Heart , Lung Blood Institute diagnostic criterion metabolic syndrome ( least 3 follow : waist circumference ≥102 cm ( male ) ≥88 cm ( female ) ; fast triglycerides≥150 mg/dL drug therapy decrease triglyceride ; fast HDLcholesterol ˂40 mg/dL ( male ) ˂50 mg/dL ( female ) drug therapy increase HDLc ; systolic blood pressure ≥130 mmHg diastolic blood pressure ≥85 mmHg antihypertensive drug therapy ; fast glycemia≥100 mg/dL Echocardiographic evidence leave ventricle diastolic dysfunction rest ( mean E'˂10,2 cm/s 4059 year ˂7,2 cm/s 6064 year ) . diagnosis diabetes mellitus accord American Diabetes Association criterion ; previous diagnosis ischemic heart disease ; moderate severe cardiac valvular disease ; left ventricle ejection fraction lower 50 % pericardial disease ; uncontrolled atrial ventricular tachyarrhythmias ; chronic kidney disease ( estimate creatinine clearance low 60 mL/min ) ; significant liver disease ( aspartate aminotransferase alanine aminotransferase equal 2.5 time upper limit normal ) ; female pregnant , plan become pregnant admit sexual activity without appropriate contraception ; lactation ; unable perform cardiopulmonary exercise test ; recent ( less 1 month ) change drug therapy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diastolic dysfunction</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Metformin</keyword>
</DOC>